Two possible cases of erenumab-induced xerostomia.

WHAT IS KNOWN AND OBJECTIVE: Erenumab is a monoclonal antibody for the prophylactic treatment of migraine. We describe the first cases of xerostomia probably induced by this drug. CASE SUMMARY: We present two patients diagnosed with chronic migraine who started treatment with erenumab and presented with dry mouth after the first and second dose. WHAT IS NEW AND CONCLUSION: Xerostomia is not described as an adverse reaction in the drug's technical datasheet. A search was made in PubMed including 'erenumab', 'fremanezumab', 'galcanezumab', 'xerostomia', and no results were found. It is necessary to identify this potential adverse reaction in order to estimate its prevalence and possible impact on patients' quality of life.